NON SMALL CELL LUNG CARCINOMA NSCLC
Clinical trials for NON SMALL CELL LUNG CARCINOMA NSCLC explained in plain language.
Never miss a new study
Get alerted when new NON SMALL CELL LUNG CARCINOMA NSCLC trials appear
Sign up with your email to follow new studies for NON SMALL CELL LUNG CARCINOMA NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy drug shows promise as First-Line treatment for advanced lung cancer
Disease control OngoingThis study compares the immunotherapy drug durvalumab with standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 669 adults with stage IV lung cancer, no specific gene mutations, and …
Matched conditions: NON SMALL CELL LUNG CARCINOMA NSCLC
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 16, 2026 12:55 UTC
-
New drug combo shows promise in lung cancer battle
Disease control OngoingThis study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better than standard chemotherapy for people with advanced non-small cell lung cancer. About 950 adults with stage IV lung cancer who had not received prior treatment took part.…
Matched conditions: NON SMALL CELL LUNG CARCINOMA NSCLC
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug combo shows promise in lung cancer fight
Disease control OngoingThis study tested two immunotherapy drugs (durvalumab and tremelimumab) alone or together against standard chemotherapy for people with advanced non-small cell lung cancer. Over 1,100 adults with no prior treatment took part. The goal was to see if the new treatments helped peopl…
Matched conditions: NON SMALL CELL LUNG CARCINOMA NSCLC
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC